SCHEMBL3763750

SCHEMBL3763750

CC(C)(C)OC(=O)N(C(=O)N1CCCCC1)c1cc[c]cc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 2/20 0.38
HTT P42858 2/20 0.38
RAB9A P51151 2/20 0.38
HPGD P15428 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ABL1 P00519 1/20 0.37
RIN1 Q13671 1/20 0.37
ALDH1A1 P00352 3/20 0.36
POLB P06746 2/20 0.36
GPR119 Q8TDV5 3/20 0.34
SRD5A1 P18405 2/20 0.32
MAPK1 P28482 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
MT-CO2 P00403 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3760646 0.87 HPGD (0.36) MAPTNPC1HTTRAB9AHPGD
SCHEMBL3763748 0.80 GPR119 (0.38) MAPTSMN1; SMN2NPC1HTTRAB9A
SCHEMBL3760367 0.77 MEN1 (0.36) MAPTSMN1; SMN2NPC1HTTRAB9A
SCHEMBL5730363 0.74 ALDH1A1 (0.45) MAPTSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL2648822 0.73 NFKB1 (0.32) MT-CO2
SCHEMBL6497833 0.70 HPGD (0.44) MAPTSMN1; SMN2NPC1HTTRAB9A
SCHEMBL28310488 0.70 PAX8 (0.46) SMN1; SMN2NPC1HTTRAB9AMEN1
SCHEMBL3765360 0.70 SMN1; SMN2 (0.41) MAPTSMN1; SMN2NPC1HTTRAB9A
SCHEMBL16161817 0.69 ALDH1A1 (0.44) MAPTSMN1; SMN2HTTHPGDMEN1
Water SCHEMBL27886068 0.68 HPGD (0.69) MAPTSMN1; SMN2NPC1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA MAPT 790/4885SMN1; SMN2 1864/4885NPC1 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.